Everman, Jamie L. http://orcid.org/0000-0002-1935-4672
Sajuthi, Satria P. http://orcid.org/0000-0001-9598-7298
Liegeois, Maude A. http://orcid.org/0000-0001-7015-5970
Jackson, Nathan D.
Collet, Erik H. http://orcid.org/0009-0007-0307-5226
Peters, Michael C.
Chioccioli, Maurizio
Moore, Camille M.
Patel, Bhavika B.
Dyjack, Nathan
Powell, Roger
Rios, Cydney
Montgomery, Michael T. http://orcid.org/0000-0002-6748-2329
Eng, Celeste
Elhawary, Jennifer R. http://orcid.org/0000-0003-3326-1680
Mak, Angel C. Y. http://orcid.org/0000-0002-5372-4198
Hu, Donglei http://orcid.org/0000-0002-0351-001X
Huntsman, Scott
Salazar, Sandra
Feriani, Luigi http://orcid.org/0000-0001-6349-7833
Fairbanks-Mahnke, Ana
Zinnen, Gianna L.
Michel, Cole R.
Gomez, Joe
Zhang, Xing
Medina, Vivian
Chu, Hong Wei
Cicuta, Pietro http://orcid.org/0000-0002-9193-8496
Gordon, Erin D.
Zeitlin, Pamela
Ortega, Victor E.
Reisdorph, Nichole
Dunican, Eleanor M. http://orcid.org/0000-0003-4014-5100
Tang, Monica http://orcid.org/0000-0001-8847-5817
Elicker, Brett M.
Henry, Travis S.
Bleecker, Eugene R.
Castro, Mario http://orcid.org/0000-0001-6328-8994
Erzurum, Serpil C.
Israel, Elliot
Levy, Bruce D.
Mauger, David T.
Meyers, Deborah A.
Sumino, Kaharu
Gierada, David S.
Hastie, Annette T. http://orcid.org/0000-0001-6607-7797
Moore, Wendy C.
Denlinger, Loren C.
Jarjour, Nizar N.
Schiebler, Mark L. http://orcid.org/0000-0002-9120-5428
Wenzel, Sally E. http://orcid.org/0000-0002-4242-0164
Woodruff, Prescott G.
Rodriguez-Santana, Jose
Pearson, Chad G. http://orcid.org/0000-0003-1915-6593
Burchard, Esteban G.
Fahy, John V.
Seibold, Max A. http://orcid.org/0000-0002-8685-4263
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL135156, R01 MD010443, R01 HL128439, P01 HL132821, P01 HL107202, HL080414, HL109146, HL146002)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10 OD028538-01A1)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM140815)
Article History
Received: 4 August 2022
Accepted: 16 April 2024
First Online: 9 May 2024
Competing interests
: On behalf of the SARP study: The following companies provided financial support for study activities at the Coordinating and Clinical Centers beyond the third year of SARP patient follow-up: AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA. These companies had no role in study design, data collection, or data analysis, nor preparation of the manuscript or decision to publish, and the only restriction on the funds was that they be used to support the SARP initiative. The authors of this manuscript report the following COIs: J.L.E. is listed as an inventor on the filed patent application by National Jewish Health, PCT/US24/11470 titled “Methods and Compositions for Treating Mucus Obstruction in Severe Asthma.” V.E.O. has received compensation for his role in Independent Data and Monitoring Committees for trials sponsored by Regeneron and Sanofi. B.M.E. receives consulting fees from Aer Therapeutics LLC, and receives stocks for service on the company board. B.M.E. is listed as one of the inventors on a filed patent application for lung image-based scoring systems that quantify mucus plug burden in the lung. T.S.H. is a stockholder and advisor for Aer Therapeutics LLC. M. Castro reports grants/research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. M. Castro receives consulting fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, Sanofi-Aventis, and Teva, and receives payment for speaker’s bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. M. Castro receives stock options from Aer Therapeutics. E.I. reports grants/research support or research materials from NHLBI, NIH, AstraZeneca, Avillion, Gossamer Bio, PCORI, Circassia, Genentech, TEVA, Sun Pharma, Laurel Pharmaceuticals, Om Pharma, Nestle, CSL Behring, AMSA, and Sanofi-Regeneron. E.I. receives consulting fees from AB Science, Allergy and Asthma Network, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Merck, NHLBI, PPS Health, Regeneron, Sanofi Genzyme, TEVA, Cowen, Guidepoint, Windrose Consulting Group, and Reach Market Research. E.I. reports royalties from Wolters Kluwer, and speaker fees from Westchester Medical Center and Clearview Health Partners. E.I. has provided expert testimony for Cambridge Medical Experts. E.I. has received compensation for participation in the Data Safety Monitoring Board for Novartis, as a member of the coordinating committee in NAEPP: National Asthma Education Prevention Program, and stock options for Vorso. B.D.L., D.T.M., K.S., and L.D. reports grant funding support for SARP study activities at the Coordinating and Clinical Centers beyond the third year of SARP patient follow-up from AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA. K.S. has received advisory fees from AstraZeneca. D.S.G. is listed as one of the inventors on a filed patent application for lung image-based scoring systems that quantify mucus plug burden in the lung. A.T.H. has received grants/research support for this study from NHLBI, and for SARP study activities at the Coordinating and Clinical Centers beyond the third year of SARP patient follow-up from AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA. W.C.M. reports grant funding support from NHLI and ALA, and reports grant funding support for SARP study activities at the Coordinating and Clinical Centers beyond the third year of SARP patient follow-up from AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA. L.D. also reports grant funding from NHLBI and ALA-ACRC, consulting fees from OM Pharma, research support/research equipment and materials from GlaxoSmithKline, Laurel, Sun Pharma, Vifor/OM Pharma, Vitaeris/CSL Behring, and Vitaflo. N.N.J. has previously received consulting fees from GlaxoSmithKline and AstraZeneca. S.E.W. is a Primary Investigator on an ongoing investigational research study with Regeneron. P.G.W. is a consultant with Regeneron, Sanofi, AstraZeneca, and Roche. J.V.F. reports grant funding from NIH/NHLBI, and reports grant funding support for SARP study activities at the Coordinating and Clinical Centers beyond the third year of SARP patient follow-up from AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA. J.V.F. is the inventor of granted patents describing thiol modified saccharides as drugs to treat mucus-associated lung disease, including asthma, patent numbers US 9,856,283; US 910,526,359; US 11,021,506. J.V.F. is listed as one of the inventors on a filed patent application for lung image-based scoring systems that quantify mucus plug burden in the lung. J.V.F. is a member of the Scientific Advisory Board and receives financial and stock options as compensation for services on the Advisory Board for Suzhou Connect Biopharmaceuticals, Ltd. J.V.F. is a member of the company board and is a consultant for Aer Therapeutics, and receives financial compensation and stocks provided as compensation for services provided. M.A.S. has received speaker fees from the Colorado Allergy and Asthma Society, and is a consultant for Escient Pharmaceuticals. M.A.S. is listed as an inventor on the filed patent application by National Jewish Health, PCT/US24/11470 titled “Methods and Compositions for Treating Mucus Obstruction in Severe Asthma.” S.P.S., M.A.L., N.D.J., E.H.C., M.C.P., M. Chioccioli, C.M.M., B.B.P., N.D., R.P., C.R., M.T.M., C.E., J.R.E., A.C.Y.M., D.H., S.H., S.S., L.F., A.F.M., G.L.Z., C.R.M., J.G., X.Z., V.M., H.W.C., P.C., E.D.G., P.Z., N.R., E.M.D., M.T., E.R.B., S.C.E., D.A.M., M.L.S., J.R.S., C.G.P., and E.G.B. declare no competing interests.